Advertisement

Topics

FDA Tells Mylan They Can’t (Yet) Approve its Generic to Advair

20:00 EDT 13 Jun 2018 | BioSpace

In a brief statement, Mylan reported that the U.S. Food and Drug Administration (FDA) had informed the company that its Generic Advair Diskus had “minor deficiencies” that would be in a Complete Response Letter.

Original Article: FDA Tells Mylan They Can’t (Yet) Approve its Generic to Advair

NEXT ARTICLE

More From BioPortfolio on "FDA Tells Mylan They Can’t (Yet) Approve its Generic to Advair"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...